| Title |
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, December 2013
|
| DOI | 10.2147/tcrm.s49428 |
| Pubmed ID | |
| Authors |
Giorgio L Colombo, Antonella Castagna, Sergio Di Matteo, Laura Galli, Giacomo Bruno, Andrea Poli, Stefania Salpietro, Alessia Carbone, Adriano Lazzarin |
| Abstract |
In the study reported here, single-tablet regimen (STR) versus (vs) multi-tablet regimen (MTR) strategies were evaluated through a cost analysis in a large cohort of patients starting their first highly active antiretroviral therapy (HAART). Adult human immunodeficiency virus (HIV) 1-naïve patients, followed at the San Raffaele Hospital, Milan, Italy, starting their first-line regimen from June 2008 to April 2012 were included in the analysis. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 21% |
| Student > Master | 8 | 17% |
| Student > Bachelor | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Other | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 12 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Agricultural and Biological Sciences | 4 | 9% |
| Economics, Econometrics and Finance | 3 | 6% |
| Immunology and Microbiology | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 11 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2014.
All research outputs
#3,083,474
of 25,394,764 outputs
Outputs from Therapeutics and Clinical Risk Management
#144
of 1,323 outputs
Outputs of similar age
#34,017
of 321,111 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 18 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,111 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.